Mesh ： Amino Acid Sequence Animals DNA-Binding Proteins / administration & dosage chemistry genetics immunology Disease Models, Animal Female Human papillomavirus 18 / immunology Humans Immunity, Cellular Macaca mulatta Mice Mice, Inbred C57BL Molecular Sequence Data Oncogene Proteins, Viral / administration & dosage chemistry genetics immunology Papillomavirus Infections / immunology prevention & control virology Papillomavirus Vaccines / administration & dosage immunology Recombinant Fusion Proteins / administration & dosage immunology T-Lymphocytes / immunology Vaccines, DNA / administration & dosage immunology

来  源：   DOI：10.1016/j.vaccine.2008.03.069   PDF(Sci-hub)   PDF(Pubmed)

Abstract：
Human papilloma-virus (HPV) infection is the major cause of cervical cancer. HPV18 is the most prevalent high-risk HPV after type 16 that accounts for the largest number of cervical cancer cases worldwide. Currently, although prophylactic vaccines have been developed, there is still an urgent need to develop therapeutic HPV vaccines for targeting tumors post-infection. In this study, we utilize a novel multi-phase strategy for HPV18 antigen development with the goal of increasing anti-HPV18 cellular immunity. Our data show that this construct can induce strong cellular immune responses against HPV18 E6 and E7 antigens in a murine model. Moreover, when applied to rhesus monkeys, this construct is also able to elicit cellular immunity. These data suggest such DNA immunogens are candidates for further study in the eventual context of immunotherapy for HPV-associated cancers.
摘要：
暂无翻译
公众号